Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Insig AI Plc (INSG.L)

LSE - LSE Delayed Price. Currency in GBp
Add to watchlist
34.00+2.00 (+6.25%)
At close: 02:25PM BST
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close32.00
Open33.72
Bid33.00 x N/A
Ask35.00 x N/A
Day's Range33.72 - 35.00
52 Week Range19.06 - 86.90
Volume34,287
Avg. Volume154,223
Market Cap35.93M
Beta (5Y Monthly)N/A
PE Ratio (TTM)68.00
EPS (TTM)0.50
Earnings DateDec 22, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Simply Wall St.

    Can Insig AI Plc's (LON:INSG) ROE Continue To Surpass The Industry Average?

    While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...

  • GlobeNewswire

    Bio-Path Granted Key Mechanism of Action U.S. Patent for BP1003

    Provides Protection and Highlights Novelty of BP1003 to Inhibit STAT3 Expression in a Variety of Difficult to Treat CancersHOUSTON, June 22, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that the United States Patent and Trademark Office has granted a new patent relating to the Company’s BP1003 p

Advertisement
Advertisement